Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CTMX by emailGet an email when CTMX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CTMX, unsubscribe in one click. Privacy
📣 What CTMX Says Is Next
first half of 2027 · “Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
1H 2027 · “Initial clinical data is anticipated in 1H 2027. o Additionally, a Phase 1/2 chemotherapy combination study including Varseta-M administered with bevacizumab, 5-fluorouracil, and leucovorin focused in 2 nd line mCRC is planned to start in Q4 2026, supporting the goal of advancing Varseta-M into earlier lines of CRC treatment, potentially replacing chemotherapy in standard of care regimens.”
Company press release, Aug 6, 2026 · SEC filing
by the end of 2026 · “CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CTMX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTMX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.